Aequitas: Hangzhou Diagens Biotech IPO Trading - Priced At Mid-Range, Weak Insti Demand
​Hangzhou Diagens Biotechnology raised US$101m in Hong Kong IPO, focusing on medical imaging products and services with insights on demand and...
204 Views
Aequitas: Hangzhou Diagens Biotechnology IPO - Aggressive Pricing Leaves No Room For Error
​Hangzhou Diagens Biotechnology aims to raise $114m in Hong Kong IPO, focusing on medical imaging products and services with past performance and...
216 Views
Pre-IPO Hangzhou Diagens Biotechnology (PHIP Updates) - The IPO Pricing Is Expensive
​Diagens' IPO pricing has "overdrawn" the growth expectation for next two years, with valuation far exceeding peers.Comfortable P/S is 10x-15x,...
214 Views
Hangzhou Diagens Biotechnology IPO: Poised for Scalable Growth from New AI Imaging Software Launch
Diagens Biotechnology kicks off HK IPO consisting of 8M H shares. The indicative offer price range is HK$95.60–112.50 per share. The company seeks...
280 Views
Primer: Hangzhou Diagens Biotechnology (HDB HK) - Mar 2026
Hangzhou Diagens Biotechnology is a rapidly growing medical device company at the forefront of applying artificial intelligence to medical...
163 Views